COMBACTE (Combatting Bacterial Resistance in Europe) is one of the projects of the "New Drugs For Bad Bugs" (ND4BB) programme.

COMBACTE is a consortium of industrial and academic partners aiming to enhance the efficiency of clinical evaluation of new antimicrobials against multi-resistant bacterial pathogens. It contains 3 networks: a clinical trial network (CLIN-Net), a laboratory network (LAB-Net), and a methodology network (STAT-Net).

COMBACTE-MAGNET: Combatting Bacterial Resistance in Europe - Molecules Against Gram Negative Infections

COMBACTE-CARE: Combatting Bacterial Resistance in Europe – Carbapenem Resistance

COMBACTE-CDI: Combatting Bacterial Resistance in Europe - Clostridium difficile Infections


The European Clinical Research Alliance for Infectious Diseases - Ecraid - advances clinical research in the field of infectious diseases by establishing a long-term, financially self-sustainable, clinical research network in Europe. Ecraid is the first network of its kind in Europe to offer a single point of access to a pan-European clinical research network for infectious diseases. 

Visit the website.

ECRAID Base: advances clinical research in the field of infectious disease through the development of Ecraid's pan-European clinical research network. Visit the website.

ECRAID Prime: is a European Adaptive Platform Trial on COVID-19 therapeutics in primary care. It will build on many years of EU investment in infrastructure for primary care trials and a mature primary care research network that has pioneered novel, efficient, platform clinical trial designs. Visit the website.


Enhanced Networking on Antimicrobial Resistance Surveillance with Next Generation Sequencing

Antimicrobial resistance (AMR) is on the rise, resulting in 700 000 deaths worldwide every year. In Croatia and Hungary, AMR is responsible for the rapid increase in morbidity and mortality rates. The EU-funded AmReSu project will strengthen the innovation capacity in AMR surveillance in Croatia and Hungary, focusing on whole genome sequencing in correlation with next-generation sequencing techniques. It will also establish an 'AMR surveillance vision'. The project relies on the cooperation of Semmelweis University in Budapest and Klinika za infektivne bolesti 'Dr. Fran Mihaljevic' in Zagreb with two internationally leading research institutions, the Laboratory of Medical Microbiology (LMM) at the University of Antwerp (UAntwerpen) and the Health Research Institute of the Balearic Islands. AmReSu will facilitate knowledge transfer, exchanges of best practices via training activities and the promotion of research excellence.

For the description of the project: Enhanced Networking on Antimicrobial Resistance Surveillance with Next Generation Sequencing | AmReSu Project | H2020 | CORDIS | European Commission (europa.eu)


Building a European partnership for Pandemic Preparedness

The aim of the project is to improve the EU’s capacity to prepare and respond to emerging infectious health threats. A consolidated European Research and Innovation Area will be built that provides the foundation of the candidate European partnership for pandemic preparedness. 

The envisioned partnership will focus on preventing, detecting and responding to emerging infectious health threats by better coordinated funding for research and innovation at EU, national (and regional) level.

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057795.